Compare IQIYI Inc - ADR (IQ) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Johnson & Johnson — how do they compare? IQIYI Inc - ADR trades at $1.02 (market cap $974.67M), while Johnson & Johnson trades at $261.43 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 634.2× IQIYI Inc - ADR's market cap, and Johnson & Johnson pays a 2.09% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Johnson & Johnson for 129 Days on average.
| IQ | JNJ | |
|---|---|---|
Market Cap | $974.67M | $618.09B |
Volume | 4,964,108 | 6,050,983 |
Sector | Media | Health |
52-Week High | $2.35 | $278.43 |
52-Week Low | $0.86 | $186.00 |
Typical Hold Time | 55 Days | 129 Days |
Enterprise Value | $2.47B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
iQIYI (IQ) trades at $1.02, up 0.49% with bearish technical signals despite recent earnings beats. The company faces revenue contraction to $27.29B in 2025 and negative net margins (-3.22%), though valuation ratios like P/S (0.25) and P/B (0.52) appear attractive. Recent news highlights AI-driven content initiatives, including the successful 'The Ferry Man' series, as management pivots to offset streaming declines.
Outlook remains challenged by sustained losses and competitive pressures, but analyst consensus leans bullish (50% Buy ratings). Key risks include execution on AI content monetization and Chinese regulatory environment. The stock's deep value profile offers speculative appeal if operational turnaround materializes.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
